Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma

  • Antal Csepregi1, 4Email author,
  • Matthias PA Ebert1, 6,
  • Christoph Röcken2, 5,
  • Regine Schneider-Stock2, 7,
  • Juliane Hoffmann1,
  • Hans-Ulrich Schulz3,
  • Albert Roessner2 and
  • Peter Malfertheiner1
Contributed equally
BMC Cancer201010:317

https://doi.org/10.1186/1471-2407-10-317

Received: 23 July 2009

Accepted: 22 June 2010

Published: 22 June 2010

Abstract

Background

The product of CDKN2A, p16 is an essential regulator of the cell cycle controlling the entry into the S-phase. Herein, we evaluated CDKN2A promoter methylation and p16 protein expression for the differentiation of hepatocellular carcinoma (HCC) from other liver tumors.

Methods

Tumor and corresponding non-tumor liver tissue samples were obtained from 85 patients with liver tumors. CDKN2A promoter methylation was studied using MethyLight technique and methylation-specific PCR (MSP). In the MethyLight analysis, samples with ≥ 4% of PMR (percentage of methylated reference) were regarded as hypermethylated. p16 expression was evaluated by immunohistochemistry in tissue sections (n = 148) obtained from 81 patients using an immunoreactivity score (IRS) ranging from 0 (no expression) to 6 (strong expression).

Results

Hypermethylation of the CDKN2A promoter was found in 23 HCCs (69.7%; mean PMR = 42.34 ± 27.8%), six (20.7%; mean PMR = 31.85 ± 18%) liver metastases and in the extralesional tissue of only one patient. Using MSP, 32% of the non-tumor (n = 85), 70% of the HCCs, 40% of the CCCs and 24% of the liver metastases were hypermethylated. Correspondingly, nuclear p16 expression was found immunohistochemically in five (10.9%, mean IRS = 0.5) HCCs, 23 (92%; mean IRS = 4.9) metastases and only occasionally in hepatocytes of non-lesional liver tissues (mean IRS = 1.2). The difference of CDKN2A-methylation and p16 protein expression between HCCs and liver metastases was statistically significant (p < 0.01, respectively).

Conclusion

Promoter methylation of CDKN2A gene and lack of p16 expression characterize patients with HCC.

Background

Hepatocellular carcinoma (HCC) shows a dramatic increase of its incidence worldwide over the last three decades [1] and is associated with a very poor prognosis [2, 3]. Except for patients accessible for surgical therapy, the 5-year survival is less than 3% [2, 3]. Chronic hepatitis B virus (HBV) with or without additional exposure to aflatoxin [4, 5], chronic hepatitis C virus (HCV), and alcohol are the main risk factors of HCC [2, 3, 6]. Diagnosis is usually made at an advanced stage of the disease, and poorly differentiated tumors are sometimes a challenge for liver-pathologists.

Many types of cancers have an abnormal control of the transition from G1 to S phase of the cell cycle. CDKN2A is regarded as tumour suppressor gene because it is frequently silenced by deletion or inactivating mutation in human cancers [79]. The product of CDKN2A, p16 is a potent cyclin-dependent kinase inhibitor and a critical negative G1-specific regulator that halts cell-cycle progression at the G1-S-phase boundary. Loss of its function can lead to uncontrolled cell proliferation [7].

Hui et al. were the first to report that p16 is commonly deleted in HCC [10]. Initially, it was believed that inactivation of p16 in patients with primary liver cancer is related to homozygous deletions and mutations of CDKN2A gene [1113]. Evidence is, however, increasing that gene silencing can also be achieved by methylation of CpG islands of the promoter region [14]. CDKN2A gene was reported to be extensively methylated in patients with HCC [15]. Indeed, methylation of CDKN2A was found not only in HCC, but also in patients with chronic liver disease [16, 17] indicating that this finding may be non-specific for liver cancer. However, previous investigations used methylation-specific PCR (MSP) [18], a technique with limited sensitivity and specificity [19, 20]. In our study, we investigated promoter methylation of CDKN2A using a novel sensitive method, MethyLight assay, in addition to the standard method of MSP, and p16 expression to identify and differentiate HCC from non-HCC liver tumors in a series of patients presenting with a liver mass.

Methods

Patients and tissue samples

Tumor and corresponding non-neoplastic liver tissue specimens were obtained from 85 patients who underwent surgical resection. Tissue samples were stored at - 80°C until analysis.

Hepatocellular carcinoma (HCC)

Patients with HCC consisted of 28 men and 5 women ranging in age from 42 to 82 (median 67 ± 11.5) years. Mean tumor size was 75.1 ± 43.4 mm (range 15 to 230 mm). HCC samples were categorized according to differentiation into well (G1; seven cases), moderately (G2; nineteen cases), or poorly (G3; seven cases) differentiated types, which correspond to Edmondson's Grades I/II, III, and IV [21, 22]. One patient (HCC patient No. 10) had a hepato-cholangiocellular carcinoma (Table 1). Regular intake of more than 60 g alcohol per day over a period of more than five years was documented in ten patients. Hereditary hemochromatosis was diagnosed in one, and chronic hepatitis C was found in ten patients. One patient (HCC patient No. 22) had a coinfection of HBV and HCV. Antibodies against HBV core protein were found in two patients (HCC patients No. 4 and No. 7) without evidence of viral replication. 13 tumors were classified as cryptogenic HCC (Table 1). Locally advanced disease was found in five cases at the time of liver resection. Alfa fetoprotein (AFP) serum level was available from 21 patients, ranging from 1.3 ng/ml to 95468 ng/ml (normal range < 7.0 ng/ml). In ten patients AFP level remained normal during follow-up. Advanced liver fibrosis or liver cirrhosis (fibrosis stages F3 to F6) according to the Ishak's scoring system [23] was confirmed in twenty-three patients (Table 1).
Table 1

Results and characteristics of patients with hepatocellular carcinoma (HCC)

Patient

Etiology

Non-tumor tissue

  

Tumor tissue

  
  

Fibrosis

Methylight

MSP

IRS

Methylight

  
   

Result

PMR

  

Result

PMR

MSP

IRS

HCC1

alcoholic

6

neg

0.08

neg

4

neg

0.14

neg

0

HCC2

cryptogenic

2

neg

0.04

neg

2

neg

3.73

pos

0

HCC3

HH

3

neg

0.01

pos

2

neg

0.04

pos

0

HCC4

alcoholic

3

neg

0.01

pos

0

neg

0.01

neg

0

HCC5

alcoholic

4

neg

1.39

neg

3

pos

100

neg

0

HCC6

cryptogenic

6

neg

0.19

pos

4

pos

14.64

pos

0

HCC7

cryptogenic

2

neg

0.01

neg

0

neg

0.41

pos

0

HCC8

alcoholic

2

neg

0.01

pos

0

pos

10.43

neg

0

HCC9

cryptogenic

5

neg

0.11

pos

4

pos

39.81

pos

0

HCC10

alcoholic*

4

neg

0.01

neg

2

pos

11.82

pos

4

HCC11

cryptogenic

2

neg

0.05

neg

2

neg

0.01

neg

3

HCC12

alcoholic

4

pos

22.44

neg

2

pos

26.86

pos

0

HCC13

alcoholic

4

neg

0.3

neg

0

pos

31.62

pos

0

HCC14

cryptogenic

1

neg

0.69

neg

3

pos

52.09

pos

0

HCC15

cryptogenic

2

neg

0.01

nd

0

pos

21.43

nd

0

HCC16

alcoholic

6

neg

0.71

pos

2

pos

100

pos

0

HCC17

cryptogenic

2

neg

0.12

nd

4

pos

22.11

nd

0

HCC18

cryptogenic

4

neg

0.15

neg

0

pos

41.06

pos

0

HCC19

alcoholic

6

neg

0.01

neg

0

pos

88.81

pos

0

HCC20

cryptogenic

2

neg

0.01

neg

2

neg

0.03

neg

0

HCC21

cryptogenic

3

neg

0.01

pos

0

pos

24.23

pos

2

HCC22

HBV/HCV

6

neg

1.46

neg

0

neg

1.92

neg

0

HCC23

HCV

1

neg

0.5

neg

0

pos

50.96

pos

0

HCC24

HCV

6

neg

0.86

neg

0

pos

7.91

pos

0

HCC25

HCV

6

neg

0.07

neg

0

neg

1.19

neg

0

HCC26

HCV

3

neg

0.19

pos

0

pos

74.13

pos

0

HCC27

HCV

6

neg

0.82

neg

0

neg

3.59

pos

0

HCC28

HCV

2

neg

2.31

neg

0

pos

11.14

pos

0

HCC29

HCV

6

neg

0.09

neg

0

pos

30.36

pos

0

HCC30

HCV

3

neg

0.19

neg

2

pos

19.78

pos

0

HCC31

HCV

5

neg

0.11

neg

0

pos

14.12

pos

4

HCC32

crpytogenic

2

neg

0.01

nd

nd

pos

88.22

nd

nd

HCC33

cryptogenic

6

neg

0.37

neg

nd

pos

100

neg

nd

HCC34

HCV

6

nd

nd

nd

0

nd

nd

nd

0

HCC35

HCV

6

nd

nd

nd

3

nd

nd

nd

0

HCC36

HCV/alcoholic

6

nd

nd

nd

0

nd

nd

nd

0

HCC37

HCV

5

nd

nd

nd

3

nd

nd

nd

0

HCC38

HCV

6

nd

nd

nd

3

nd

nd

nd

0

HCC39

HCV

5

nd

nd

nd

2

nd

nd

nd

0

HCC40

HCV

5

nd

nd

nd

6

nd

nd

nd

5

HCC41

HCV/alcoholic

3

nd

nd

nd

2

nd

nd

nd

0

HCC42

HCV/alcoholic

6

nd

nd

nd

1

nd

nd

nd

0

HCC43

HCV/alcoholic

na

nd

nd

nd

nd

nd

nd

nd

0

HCC44

HCV

na

nd

nd

nd

nd

nd

nd

nd

0

HCC45

HCV

na

nd

nd

nd

nd

nd

nd

nd

0

HCC46

HCV

na

nd

nd

nd

nd

nd

nd

nd

0

HCC47

HCV

na

nd

nd

nd

nd

nd

nd

nd

0

HCC48

HCV

na

nd

nd

nd

nd

nd

nd

nd

0

HCC, hepatocellular carcinoma; PMR, percentage of methylated reference (%); MSP, methylation specific PCR;

IRS = Immunoreactivity score, nd, not done; na, not available; AFP, alfa fetoprotein; * the tumor was considered as a mixed form of HCC and CCC; HBV, hepatitis B virus; HCV, hepatitis C virus;

Bile duct cancer (CCC)

Tissue samples were obtained from 11 patients (4 men, 7 women) with adenocarcinoma of biliary tree and gall bladder with a mean age of 60.3 ± 8.1 years (range from 42 to 73 years) and graded as well (G1; one case), moderately (G2; eight cases), or poorly (G3; two cases) differentiated tumors. Two patients (CCC patients No. 9 and No. 10) developed advanced liver fibrosis (Table 2).
Table 2

Results and characteristics of patients with cholangiocellular carcinoma and benign liver tumors

Patient

Liver disease/

Non-tumor tissue

  

Tumor tissue

  
 

Primary cancer

Fibrosis

Methylight

MSP

IRS

Methylight

MSP

IRS

  

score

Result

PMR

  

Result

PMR

  

Cholangiocellular carcinoma (CCC)

CCC1

bile duct

0

neg

0.01

pos

0

neg

0.01

neg

6

CCC2

bile duct

2

neg

0.01

neg

0

neg

0.04

neg

0

CCC3

bile duct

0

neg

0.01

neg

0

neg

0.01

pos

6

CCC4

bile duct

0

neg

0.01

neg

0

neg

0.8

pos

0

CCC5

gall bladder

0

neg

0.01

pos

0

pos

25.86

pos

2

CCC6

bile duct

0

neg

0.01

pos

2

neg

0.01

pos

2

CCC7

bile duct

2

neg

0.07

neg

0

neg

0.1

neg

5

CCC8

gall bladder

0

neg

0.01

neg

0

neg

3.28

neg

0

CCC9

bile duct

6

neg

0.01

neg

nd

neg

0.01

neg

nd

CCC10

bile duct

4

neg

0.49

neg

nd

neg

0.27

neg

nd

CCC11

gall bladder

1

neg

0.4

nd

nd

neg

0.01

nd

nd

Benign liver tumors (B)

B1

FNH

0

neg

0.34

neg

0

neg

0.05

neg

2

B2

FNH

0

neg

0.05

neg

0

neg

0.25

neg

5

B3

hepatic adenoma

0

neg

0.01

nd

0

neg

0.01

nd

2

B4

FNH

0

neg

0.62

neg

2

neg

0.07

neg

0

B5

FNH

0

neg

0.1

nd

nd

neg

0.04

nd

nd

B6

FNH

0

neg

0.07

nd

nd

neg

1.36

nd

nd

B7

FNH

0

neg

0.03

nd

nd

neg

0.26

nd

nd

PMR, percentage of methylated reference (%); MSP, methylation specific PCR, IRS = Immunoreactivity score; nd, not done; CCC, cholangiocellular carcinoma; FNH, focal nodular hyperplasia;

Benign liver tumors

Samples from seven patients (1 man, 6 women) with a benign liver tumor, i.e. focal nodular hyperplasia (n = 6) or liver adenoma (n = 1) were also studied (Table 2). Age of patients ranged from 22 to 47 (mean 40 ± 6) years. Advanced liver fibrosis was not detected in this patients' group.

Liver metastases (M)

Tissue samples were also obtained from 34 patients (21 men, 13 women) with liver metastasis of colorectal (n = 29), gastric (n = 2), renal (n = 1), and breast (n = 2) cancers. Age of patients ranged from 32 to 82 (median 63.9 ± 8.2) years. Liver metastases were also categorized according to differentiation into well (G1; two case), moderately (G2; twenty-five cases), or poorly (G3; seven cases) differentiated carcinomas (Table 3). Advanced liver fibrosis (Ishak's stages F3 to F6) [23] was found only in one non-cancer liver tissue (M7) (Table 3).
Table 3

Results and characteristics of patients with liver metastasis

Patient

Primary cancer

Non-tumor tissue

  

Tumor tissue

  
  

Fibrosis

Methylight

MSP

IRS

Methylight

MSP

IRS

  

score

Result

PMR

  

Result

PMR

  

Liver metastasis (M)

M1

breast

1

neg

0.05

nd

3

neg

0.02

nd

6

M2

breast

0

neg

0.04

nd

2

neg

0.01

nd

6

M3

colorectal

0

neg

0.01

nd

0

neg

0.01

nd

4

M4

colorectal

0

neg

0.01

nd

0

neg

0.01

nd

6

M5

colorectal

0

neg

0.01

nd

0

neg

0.01

nd

3

M6

colorectal

0

neg

0.01

nd

0

neg

0.01

nd

6

M7

colorectal

4

neg

0.01

nd

0

neg

0.01

nd

5

M8

colorectal

0

neg

0.01

nd

0

neg

0.01

nd

5

M9

colorectal

0

neg

0.01

nd

0

neg

0.01

nd

6

M10

colorectal

0

neg

0.01

nd

0

neg

0.01

nd

5

M11

colorectal

0

neg

0.01

nd

2

pos

39.55

nd

4

M12

colorectal

0

neg

0.01

nd

0

neg

0.01

nd

6

M13

colorectal

0

neg

0.01

neg

0

neg

0.01

neg

6

M14

colorectal

0

neg

0.02

pos

0

neg

0.01

pos

6

M15

colorectal

0

neg

0.01

neg

0

pos

52.18

neg

6

M16

colorectal

0

neg

0.09

neg

0

neg

0.74

neg

6

M17

colorectal

0

neg

0.39

neg

2

neg

0.04

neg

6

M18

colorectal

0

neg

0.73

neg

0

neg

0.12

neg

5

M19

colorectal

0

neg

0.15

neg

0

neg

0.01

neg

5

M20

colorectal

0

neg

0.17

pos

2

neg

0.01

neg

4

M21

colorectal

0

neg

0.8

neg

3

pos

57.82

pos

0

M22

colorectal

0

neg

0.54

pos

2

neg

0.35

neg

5

M23

colorectal

2

neg

0.55

pos

0

neg

0.51

neg

6

M24

colorectal

0

neg

0.38

neg

0

pos

9.88

pos

0

M25

colorectal

0

neg

0.08

pos

0

pos

6.48

neg

5

M26

gastric

0

neg

0.01

pos

nd

neg

0.01

neg

nd

M27

gastric

0

neg

0.39

neg

nd

neg

0.15

neg

nd

M28

colorectal

0

neg

0.09

neg

nd

pos

25.19

neg

nd

M29

colorectal

0

neg

0.85

pos

nd

neg

0.07

pos

nd

M30

colorectal

0

neg

0.86

neg

nd

neg

0.49

neg

nd

M31

colorectal

0

neg

0.55

pos

nd

neg

1.19

pos

nd

M32

renal

0

neg

0.01

nd

nd

neg

0.01

nd

nd

M33

colorectal

1

neg

0.08

nd

nd

neg

0.85

nd

nd

M34

colorectal

0

neg

0.03

nd

nd

neg

0.01

nd

nd

PMR, percentage of methylated reference (%); MSP, methylation specific PCR; nd, not done;

Tissue samples for immunohistochemistry

Only tissue slides were available for immunohistochemical analysis from further 23 patients [HCC (n = 15) (Table 1) and chronic hepatitis C (n = 8)]. All the 15 HCC patients had a HCV-related chronic liver disease, and four consumed also regularly alcohol. Core antibodies against HBV were present in two patients. Liver cirrhosis was confirmed in six samples.

The study was approved by the Ethics Committee of the Otto-von-Guericke University of Magdeburg.

DNA extraction and sodium bisulfit modification

Genomic DNA was extracted using proteinase K digestion and was modified by sodium bisulfit (CpGenome™ DNA Modification Kit, Q-Biogene Heidelberg, Germany) as reported previously [24, 25].

MethyLight assay

Genomic DNA was analyzed by MethyLight technique after bisulfite conversion as reported previously [19, 20]. Briefly, three oligonucleotids were used in every reaction. Two locus-specific PCR primers flanked an oligonucleotide probe with a 5' fluorescent reported dye (6FAM) and a 3'quencher dye (BHQ-1). Primer and probe sequences for CDKN2A promoter (GeneBank accession number GI 21886808) were: forward primer (bp 20012-20033) 5'-tgg-agt-ttt-cgg-ttg-att-ggt-t-3'; reverse primer (bp 20081-20060): 5'-aac-aac-gcc-cgc-acc-tcc-c-3'; oligonucleotide probe sequence (5'-3') (bp 20060-20043): 6FAM-acc-cga-ccc-cga-acc-gcg-BHQ-1. PCR reaction resulted in a 70-bp product including 8 CpG islands localized on the first exon of the gene. The gene of interest was then amplified and normalized to a reference set (β-actin = ACTB) to normalize for input DNA. The specificity of reactions for methylated DNA was confirmed using CpGenome Universal Methylated DNA [(Chemicon International Inc., CA, USA (subsidiary or Serologicals) catalog #S7821)]. TaqMan PCR reactions were performed in parallel with primers specific for the bisulfite-converted methylated sequence for a particular locus and with ACTB reference primers. The ratio between values was calculated in these two TaqMan analyses, using this approach the degree of methylation at that locus was determined. The extent of methylation at a specific locus was determined by the following formula: [(gene/actb)sample: (gene/actb)SssI-treated genomic DNA]* 100. Samples with ≥ 4% of PMR (percentage of methylated reference) were regarded as hypermethylated.

Methylation-specific PCR (MSP)

The methylation status of CDKN2A was also evaluated by MSP as described previously[18, 26]. In brief, DNA was subjected to bisulfit modification and was amplified using two primers specific for either methylated or unmethylated sequences [18]. Primer sequences for unmethylated reactions were sense: 5'-tta-tta-gag-ggt-ggg-gtg-gat-tgt-3' and anti-sense: 5'-caa-ccc-caa-acc-aca-acc-ata-a-3', which amplified a 151 bp product. Primer sequences for methylated reactions were sense: 5'-tta-tta-gag-ggt-gcg-gat-cgc-3 and anti-sense: 5'-gac-ccc-gaa-ccg-cga-ccg-taa-3', which amplified a 150 bp product. CpGenome™ Universal Methylated DNA (Q-Biogene, Heidelberg, Germany) was used as positive control. DNA from normal lymphocytes served as negative control for methylated alleles. PCR was performed as described previously [26]. PCR products were run on polyacrylamide gels, followed by silver-staining.

Immunohistochemistry

p16 expression was studied on formalin-fixed and paraffin embedded tissue samples. Briefly, 3-5 μm thick tissue sections were deparaffinized in xylol and rehydrated in a graded alcohol series. Endogenous biotin was blocked using the Avidin/Biotin Blocking kit (2 × 15 minutes; Vector Laboratories, Inc., Burlingame, CA). Immunostaining was performed with polyclonal anti-p16 antibody directed against the entire region of the human p16 protein (1:100; Quartett, Berlin, Germany). Incubation with the primary antibody was performed in a moist chamber at 37°C for 1 hour. Rabbit-anti-mouse IgG (30 minutes, room temperature; Vector Laboratories Inc.) served as a secondary antibody. The immunoreaction was visualized with an streptavidin-biotin complex, using the Vectastain ABC alkaline phosphatase kit (distributed by CAMON, Wiesbaden, Germany). FastRed (Zytomed, Berlin, Germany) served as chromogen. The specimens were counter-stained with hematoxylin. Omission of the primary antibody served as a negative control.

Immunoreactivity Score (IRS)

For quantification of immunohistochemical results, a numerical scoring system was applied. Only nuclear staining was considered as positive. The observed expression of p16 in hepatocytes and tumor cells was assessed using two categories. Category A documented the number of immunoreactive cells as 0 (no reactive cells), 1 (< 10%), 2 (11 to 50%), and 3 (> 50%). Category B documented the intensity of immunostaining as 0 (no immunostaining), 1 (weak), 2 (moderate), and 3 (strong). Finally, values for category A and B were added to construct an "immunoreactivity score" (IRS) ranging from 0 to 6.

Statistical analysis

PMR (percentage of methylated reference) values of Methylight assays were dichotomized for statistical purposes as reported previously [19, 20]. PMR values of tumor and non-tumor samples were compared by Kolmogorov-Smirnov test. Differences in promoter methylation rate were analysed between cancer and non-tumor tissues using Fisher's exact test. All statistical tests were two-sided, with p < 0.05 considered statistically significant difference.

Results

MethyLight assay

Using Methylight assay, methylation status of 8 CpG islands of the first exon of CDKN2A was evaluated in 33 HCCs and the corresponding non-tumor liver samples. The mean PMR of HCC samples was 31.41 ± 27.63% (range 0.01 to 100%) (Table 1). Twenty-three patients with HCC (69.7%) showed a PMR > 4% and were regarded as hypermethylated. The CDKN2A hypermethylation positive HCCs showed a mean PMR of 42.34 ± 27.8% (range 7.91 to 100%) (Table 1). A methylation of CpG islands was detected in 4 (57%) of 7 well-differentiated, 15 (79%) of 19 moderately differentiated, and 4 (57%) of 7 poorly differentiated HCCs. The frequency of promoter hypermethylation between patients with non-HCV induced HCC and those with HCV-induced HCC was not different (69% vs. 70%; ns). The mean PMR of the corresponding non-cancer liver tissues was 1.15 ± 1.64% (range 0.01 to 22.41). All but one (HCC patient No. 21) corresponding non-tumor samples obtained from patients with HCC were found to have an unmethylated CDKN2A promoter (Figure 1).
Figure 1

Results of Methylight analysis. Frequency of promoter methylation of CDKN2A gene is shown in patients with liver tumors detected by Methylight assay.

Next, we assessed the frequency of CDKN2A methylation in tumor and non-tumor tissue samples of 34 patients with liver metastases (Table 3) and 11 patients with adenocarcinomas of the biliary tract and gall bladder (CCC-group) as well as from 7 patients with benign liver tumors (Table 2).

None of tissue samples with benign liver pathology obtained from patients with non-HCC (altogether 59 samples including lesional samples of patients with benign liver tumors) showed CpG methylation. Liver metastases of 6 colorectal cancers (20.7%) had a mean PMR of 39.23% (range 25.18 to 52.18%). Only one tumor sample (9%) of the CCC-group had a PMR of 25.86% (Tables 2 and 3) (Figure 1). PMR in liver metastases was comparable to those results obtained from patients with HCC.

MSP analysis

Tumor und non-tumor tissue samples from 30 patients with HCC were studied using MSP. 30% of the non-tumor and 70% of the tumor samples were found to be hypermethylated. There was no significant difference between the HCV-induced tissue probes (80%) and those from patients with HCC not related to HCV (65%) in terms of methylation of promoter region. 17 HCC samples were hypermethylated with both methods (MethyLight and MSP). None of the MSP-positive non-tumor samples showed hypermethylation analysed by MethyLight. Altogether, about half of cancer probes (21 HCCs, 1 CCC, 6 liver metastases) were found hypermethylated in MSP analysis. Among patients with MSP-positive metastatic colorectal cancer, only 2 (patients 21 and 24) showed a methylated promoter also in MethyLight analysis (Table 3). It was of interest that 32% of the non-neoplastic liver tissue samples proved methylated in MSP analysis (Figure 2).
Figure 2

Results of MSP analysis. Frequency of promoter methylation of CDKN2A gene is shown in patients with liver tumors detected by MSP.

Immunohistochemical staining

148 tissue sections were obtained from 81 patients [HCC (n = 36), CCC-group (n = 8), benign liver tumors (n = 4), liver metastasis (n = 25) and chronic hepatitis C (n = 8)] and were studied by immunohistochemistry for p16 protein expression. Non-cancer samples (n = 75) showed only a weak immunoreactivity for p16 (mean IRS: 1.24) in few hepatocytes (Figures 3 and 4). While samples (n = 45) without significant liver fibrosis (F0 to F2) expressed no p16 (mean IRS: 0.36), immunostaining was significantly enhanced in samples (n = 30) with advanced liver fibrosis or cirrhosis (F3 to F6) (mean IRS: 2.6) (p < 0.01) (Figure 5). Here, p16 was mainly expressed by hepatocytes lining the portal tracts and fibrous septa as well as by cells of ductular proliferations. Nuclear p16 expression was absent in the vast majority of HCC samples (Figure 3). Only 5 samples (11%, mean IRS: 0.47) obtained from moderately differentiated HCCs expressed p16 in the nucleus. In contrast, metastatic cancer probes (23/25) showed a strong p16 expression (mean IRS: 4.9) (p < 0.01) (Figure 6). A complete loss of nuclear p16 expression was seen only in two remaining samples from patients with colorectal cancer (patients 21 and 24) (Table 3). Tissue samples obtained from patients of the CCC-group (IRS: 2.6) or with benign liver tumors (IRS: 1.75) showed only a moderate p16 immunostaining.
Figure 3

Quantitative differences of p16 protein expression. In liver tumors and non-neoplastic tissue samples the quantitative differences of p16 expression evaluated by immunohistochemical detection of p16 using an immunoreactivity score (IRS) are shown.

Figure 4

Immunohistochemical expression of p16 in non-neoplastic liver tissue and hepatocellular carcinoma. A moderately differentiated HCC is completely immunonegative for p16 (left). The non-neoplastic liver tissue shows immunostaining for p16 in scattered ductular reactions and mild cytoplasmic immunostaining in few periportal and periseptal hepatocytes (right). Anti-p16-antibody. Hematoxylin-counterstain.

Figure 5

Immunohistochemical expression of p16 in non-tumor liver sample. The non-neoplastic liver tissue shows strong immunostaining for p16 in the ductular reactions and mild cytoplasmic immunostaining in few periportal hepatocytes. Anti-p16-antibody. Hematoxylin-counterstain.

Figure 6

Immunohistochemical detection of p16 in a liver metastasis. Liver metastasis of a moderately differentiated colorectal cancer with strong cytoplasmic and also nuclear expression of p16 in tumor cells. Non-neoplastic liver tissue adjacent to colorectal cancer metastasis is completely devoid of p16 expression. Anti-p16-antibody. Hematoxylin-counterstain.

The difference of CDKN2A-methylation and p16 protein expression between HCCs and liver metastases was statistically significant (p < 0.01, respectively). Using the Spearman non-parametric test, no correlation between nuclear p16 expression detected by immunohistochemical staining and CDKN2A promoter methylation using Methylight assay could be shown.

Discussion

CDKN2A encodes a cyclin-dependent kinase inhibitor, a negative G1-specific regulator of cell cycle and was reported to be inactivated through extensive CpG methylation in hepatitis virus-induced HCC [15]. However, CpG islands of CDKN2A were shown to be also methylated using MSP [18], a technique having limited sensitivity and specificity [19, 20], in patients with chronic liver diseases without HCC [16, 17]. In order to further clarify this issue, in the first step of our analysis, we focused on epigenetic changes of CDKN2A evaluating the methylation status of CpG islands on the first exon. MethyLight provides a sensitive tool for detecting CpG methylation [19, 20] and also allows to quantitatively assess the grade of methylation. Our findings indicate that methylation of CpG islands at the 5'end of the first exon of CDKN2A detected by MethyLight, but not by MSP, may serve as a specific marker of HCC since it was frequently found in HCCs and detected only in one non-cancer sample. Epigenetic changes of CpG islands are probably related not only to chronic viral hepatitis as suggested in several previous reports [16, 17, 27]. In our study patients with non-HCV induced HCC showed the same frequency of promoter hypermethylation as HCV induced HCCs. Hypermethylation of CDKN2A gene was not found in any of the extralesional liver tissue samples obtained from patients with chronic hepatitis C. 20% of patients with liver metastases of colorectal cancers had methylated CpG islands and that frequency is somewhat lower than reported in the literature [25, 28, 29].

In previous studies it was shown that p16 was expressed at very low levels in mammalian tissues suggesting that this protein may have no impact on the normal development of cells [30, 31]. In our study, non-cancer liver samples without advanced fibrosis failed to express p16 in the nucleus suggesting that p16 is expressed only at low levels in non-neoplastic tissue. In contrast, in patients with severe liver fibrosis or cirrhosis which are considered as a preneoplastic condition for HCC, an increased nuclear p16 expression was observed. Nuclear p16 expression was not detected in the majority of HCCs indicating that loss of p16 may be a common event during hepatocarcinogensis [15]. The absence of p16 expression resulting from either methylation or mutation of CDKN2A gene may probably reflect increased selection pressure at this neoplastic stage for loss of p16 expression. In our study, we found no correlation between methylation of the first exon of CDKN2A gene and nuclear expression of p16.

Data on p16 protein expression in liver metastases are scarce. Dai et al reported [32] that 89% of colon adenomas, 65% of colon carcinomas and 100% of liver metastasis of colon cancer expressed p16. In line with these results, liver metastases from colon cancers showed also in our study a strong p16 expression. Overexpression of p16 in metastatic tissue samples appeared to be paradoxical and was seen in several primary gastrointestinal tumors [3234]. The precise reason why negative regulators of the cell cycle often display increased expression is unknown at present and remains to be elucidated.

Conclusions

In summary, using MethyLight assay for epigenetic studies of CDKN2A in patients with liver tumors we showed that CDKN2A methylation is a putative marker of HCC. MSP compared to MethyLight seems to be unspecific in patients with liver tumors.

Our data also indicate that the combined analysis of CDKN2A methylation and immunohistochemical staining for p16 expression might be an approach to distinguish HCC from non-HCC liver tumors and liver metastases. Moreover, it is of particular interest that p16 expression seems to correlate with the grade of liver fibrosis. This finding deserves further studies.

Notes

Declarations

Acknowledgements

A. Csepregi is supported by the "Rotationsprogramm" of the NBL-3 of the BMBF (Förderkennzeichen 01ZZ0407). M. P. Ebert is supported by a grant from the DFG (187/4-1) and the Heisenberg-Programme (Eb 187/5-1). No funding was received.

Authors’ Affiliations

(1)
Department of Gastroenterology, Hepatology, and Infectious Diseases, Otto-von-Guericke University
(2)
Institute of Pathology, Otto-von-Guericke University
(3)
Department of Surgery, Otto-von-Guericke University
(4)
Department of Medicine, Hufeland Klinikum GmbH Bad Langensalza
(5)
Institute of Pathology, Christian-Albrecht University
(6)
Department of Medicine II, Klinikum rechts der Isar, Technical University
(7)
Institute of Pathology, Friedrich-Alexander University of Erlangen-Nürnberg

References

  1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA: Continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003, 139: 817-823.View ArticlePubMedGoogle Scholar
  2. Bosch X, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis. 1999, 19: 271-285. 10.1055/s-2007-1007117.View ArticlePubMedGoogle Scholar
  3. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet. 2003, 362: 1907-1917. 10.1016/S0140-6736(03)14964-1.View ArticlePubMedGoogle Scholar
  4. Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and HBV: a prospective study of 22,707 men in Taiwan. Lancet. 1981, 2: 1129-1132. 10.1016/S0140-6736(81)90585-7.View ArticlePubMedGoogle Scholar
  5. Wogan GN: Aflatoxin as a human carcinogen. Hepatology. 1999, 30: 573-575. 10.1002/hep.510300231.View ArticlePubMedGoogle Scholar
  6. Colombo M: Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis. 1999, 19: 263-269. 10.1055/s-2007-1007116.View ArticlePubMedGoogle Scholar
  7. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDJ4. Nature (Lond). 1993, 366: 704-707. 10.1038/366704a0.View ArticleGoogle Scholar
  8. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV: A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994, 264: 436-440. 10.1126/science.8153634.View ArticlePubMedGoogle Scholar
  9. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond). 1994, 368: 753-756. 10.1038/368753a0.View ArticleGoogle Scholar
  10. Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, Hirohashi S: Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology. 1996, 24: 575-579. 10.1002/hep.510240319.View ArticlePubMedGoogle Scholar
  11. Biden K, Young J, Buttenshaw R, Searle J, Cooksley G, Xu DB, Leggett B: Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology. 1997, 25: 593-597. 10.1002/hep.510250317.View ArticlePubMedGoogle Scholar
  12. Chaubert P, Gayer R, Zimmermann A, Fontolliet C, Stamm B, Bosman F, Shaw P: Germ-line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma. Hepatology. 1997, 25: 1376-1381. 10.1002/hep.510250613.View ArticlePubMedGoogle Scholar
  13. Baek MJ, Piao Z, Kim N-G, Park C, Shin E-C, Park J-H, Jung H-J, Kim CG, Kim H: p16 is a major inactivation target in hepatocellular carcinoma. Cancer. 2000, 89: 60-68. 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3.View ArticleGoogle Scholar
  14. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC: 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995, 1: 686-692. 10.1038/nm0795-686.View ArticlePubMedGoogle Scholar
  15. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H: p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology. 1999, 116: 394-400. 10.1016/S0016-5085(99)70137-X.View ArticlePubMedGoogle Scholar
  16. Kaneto H, Sasaki S, Yamamoto H, Itoh F, Toyota M, Suzuki H, Ozeki I, Iwata N, Ohmura T, Satoh T, Karino Y, Satoh T, Toyota J, Satoh M, Endo T, Omata M, Imai K: Detection of hypermethylation of the p16INK4a promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut. 2001, 48: 372-377. 10.1136/gut.48.3.372.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Li X, Hui A-M, Sun L, Hasegawa K, Torzilli G, Minagawa M, Takayama T, Makuuchi M: p16INK4a hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin Cancer Res. 2004, 10: 7484-7489. 10.1158/1078-0432.CCR-04-1715.View ArticlePubMedGoogle Scholar
  18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996, 93: 9821-9826. 10.1073/pnas.93.18.9821.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW: Methy-Light: a high-throughput assay to measure DNA methylation. Nucleic Acid Res. 2000, 28: E32-10.1093/nar/28.8.e32.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV, Laird PW, Skinner KA: Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000, 60: 5021-5026.PubMedGoogle Scholar
  21. Edmondson HA, Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954, 7: 462-503. 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
  22. MacSween RNM, Burt AD, Portman BC, Ishak KG, Scheuer PJ, Anthony PP: Pathology of the liver. 2002, Edinburgh, London Churchill LivingstoneGoogle Scholar
  23. Ishak K, Baptista A, Bianchi L, Cellea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol. 1995, 22: 966-969. 10.1016/0168-8278(95)80226-6.View ArticleGoogle Scholar
  24. Ebert MP, Yu J, Hoffmann J, Rocco A, Rocken C, Kahmann S, Muller O, Korc M, Sung JJ, Malfertheiner P: Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol. 2003, 21: 1708-1714. 10.1200/JCO.2003.10.017.View ArticlePubMedGoogle Scholar
  25. Ebert MPA, Mooney SH, Tonnes-Priddy L, Lograsso J, Hoffmann J, Chen J, Röcken C, Schulz H-U, Malfertheiner P, Lofton-Day C: Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia. 2005, 7: 771-778. 10.1593/neo.05235.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Schneider-Stock R, Boltze C, Peters B, Höpfner T, Meyer F, Lippert H, Roessner A: Differences in loss of p16INK4 protein expression by promoter methylation between left- and right-sided primary colorectal carcinomas. Int J Oncol. 2003, 23: 1009-1013.PubMedGoogle Scholar
  27. Shim Y-H, Yoon G-S, Choi H-J, Chung YH, Yu E: p16 hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis. Cancer Lett. 2003, 190: 213-219. 10.1016/S0304-3835(02)00613-4.View ArticlePubMedGoogle Scholar
  28. Norrie MWA, Hawkins NJ, Todd AV, Meagher AP, O'Connor TW, Ward RL: Inactivation of p16INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. J Surg Oncol. 2003, 84: 143-150. 10.1002/jso.10310.View ArticlePubMedGoogle Scholar
  29. Prall FP, Ostwald C, Weirich V, Nizze H: p16INK4a promoter methylation and 9p21 allelic loss in colorectal carcinomas: relation with immunohistochemical p16INK4a expression and tumor budding. Human Pathol. 2006, 37: 578-585. 10.1016/j.humpath.2006.01.005.View ArticleGoogle Scholar
  30. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996, 85: 27-37. 10.1016/S0092-8674(00)81079-X.View ArticlePubMedGoogle Scholar
  31. Zindy F, Quelle DE, Roussel MF, Sherr CJ: Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene. 1997, 15: 203-211. 10.1038/sj.onc.1201178.View ArticlePubMedGoogle Scholar
  32. Dai CY, Furth EE, Mick R, Koh J, Takayama T, Niitsu Y, Enders GH: p16INK4a expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology. 2000, 119: 929-942. 10.1053/gast.2000.17952.View ArticlePubMedGoogle Scholar
  33. Palmqvist R, Rutegard JN, Bozoky B, Landberg G, Stenling R: Human colorectal cancers with an intact p16/cyclinD/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol. 2000, 157: 1947-1953.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Tsujie M, Yamamoto H, Tomita N, Sugita Y, Ohue M, Sakita I: Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. Oncology. 2000, 58: 126-136. 10.1159/000012089.View ArticlePubMedGoogle Scholar
  35. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/317/prepub

Copyright

© Csepregi et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement